NCT02599649 - Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

January 30, 2019

Study Completion Date

January 30, 2019

Conditions

Leukemia

Interventions

DRUG

Lirilumab

3 mg/kg by vein every 4 weeks.

DRUG

Nivolumab

3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.

DRUG

Azacitidine

75 mg/m\^2 by vein for 7 days of a 28 day cycle.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston